Cargando…
In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis
Given the strong clinical evidence that copper levels are significantly elevated in a wide spectrum of tumors, copper homeostasis is considered as an emerging target for anticancer drug design. Monitoring copper levels in vivo is therefore of paramount importance when assessing the efficacy of coppe...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276294/ https://www.ncbi.nlm.nih.gov/pubmed/30555570 http://dx.doi.org/10.7150/thno.29840 |
_version_ | 1783377988895637504 |
---|---|
author | Parmar, Arvind Pascali, Giancarlo Voli, Florida Lerra, Luigi Yee, Eugene Ahmed-Cox, Aria Kimpton, Kathleen Cirillo, Giuseppe Arthur, Andrew Zahra, David Rahardjo, Gita Liu, Guo Jun Lengkeek, Nigel Saletta, Federica Charil, Arnaud Kavallaris, Maria Vittorio, Orazio |
author_facet | Parmar, Arvind Pascali, Giancarlo Voli, Florida Lerra, Luigi Yee, Eugene Ahmed-Cox, Aria Kimpton, Kathleen Cirillo, Giuseppe Arthur, Andrew Zahra, David Rahardjo, Gita Liu, Guo Jun Lengkeek, Nigel Saletta, Federica Charil, Arnaud Kavallaris, Maria Vittorio, Orazio |
author_sort | Parmar, Arvind |
collection | PubMed |
description | Given the strong clinical evidence that copper levels are significantly elevated in a wide spectrum of tumors, copper homeostasis is considered as an emerging target for anticancer drug design. Monitoring copper levels in vivo is therefore of paramount importance when assessing the efficacy of copper-targeting drugs. Herein, we investigated the activity of the copper-targeting compound Dextran-Catechin by developing a [(64)Cu]CuCl(2) PET imaging protocol to monitor its effect on copper homeostasis in tumors. Methods: Protein expression of copper transporter 1 (CTR1) in tissue microarrays representing 90 neuroblastoma patient tumors was assessed by immunohistochemistry. Western blotting analysis was used to study the effect of Dextran-Catechin on the expression of CTR1 in neuroblastoma cell lines and in tumors. A preclinical human neuroblastoma xenograft model was used to study anticancer activity of Dextran-Catechin in vivo and its effect on tumor copper homeostasis. PET imaging with [(64)Cu]CuCl(2) was performed in such preclinical neuroblastoma model to monitor alteration of copper levels in tumors during treatment. Results: CTR1 protein was found to be highly expressed in patient neuroblastoma tumors by immunohistochemistry. Treatment of neuroblastoma cell lines with Dextran-Catechin resulted in decreased levels of glutathione and in downregulation of CTR1 expression, which caused a significant decrease of intracellular copper. No changes in CTR1 expression was observed in normal human astrocytes after Dextran-Catechin treatment. In vivo studies and PET imaging analysis using the neuroblastoma preclinical model revealed elevated [(64)Cu]CuCl(2) retention in the tumor mass. Following treatment with Dextran-Catechin, there was a significant reduction in radioactive uptake, as well as reduced tumor growth. Ex vivo analysis of tumors collected from Dextran-Catechin treated mice confirmed the reduced levels of CTR1. Interestingly, copper levels in blood were not affected by treatment, demonstrating potential tumor specificity of Dextran-Catechin activity. Conclusion: Dextran-Catechin mediates its activity by lowering CTR1 and intracellular copper levels in tumors. This finding further reveals a potential therapeutic strategy for targeting copper-dependent cancers and presents a novel PET imaging method to assess patient response to copper-targeting anticancer treatments. |
format | Online Article Text |
id | pubmed-6276294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-62762942018-12-14 In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis Parmar, Arvind Pascali, Giancarlo Voli, Florida Lerra, Luigi Yee, Eugene Ahmed-Cox, Aria Kimpton, Kathleen Cirillo, Giuseppe Arthur, Andrew Zahra, David Rahardjo, Gita Liu, Guo Jun Lengkeek, Nigel Saletta, Federica Charil, Arnaud Kavallaris, Maria Vittorio, Orazio Theranostics Research Paper Given the strong clinical evidence that copper levels are significantly elevated in a wide spectrum of tumors, copper homeostasis is considered as an emerging target for anticancer drug design. Monitoring copper levels in vivo is therefore of paramount importance when assessing the efficacy of copper-targeting drugs. Herein, we investigated the activity of the copper-targeting compound Dextran-Catechin by developing a [(64)Cu]CuCl(2) PET imaging protocol to monitor its effect on copper homeostasis in tumors. Methods: Protein expression of copper transporter 1 (CTR1) in tissue microarrays representing 90 neuroblastoma patient tumors was assessed by immunohistochemistry. Western blotting analysis was used to study the effect of Dextran-Catechin on the expression of CTR1 in neuroblastoma cell lines and in tumors. A preclinical human neuroblastoma xenograft model was used to study anticancer activity of Dextran-Catechin in vivo and its effect on tumor copper homeostasis. PET imaging with [(64)Cu]CuCl(2) was performed in such preclinical neuroblastoma model to monitor alteration of copper levels in tumors during treatment. Results: CTR1 protein was found to be highly expressed in patient neuroblastoma tumors by immunohistochemistry. Treatment of neuroblastoma cell lines with Dextran-Catechin resulted in decreased levels of glutathione and in downregulation of CTR1 expression, which caused a significant decrease of intracellular copper. No changes in CTR1 expression was observed in normal human astrocytes after Dextran-Catechin treatment. In vivo studies and PET imaging analysis using the neuroblastoma preclinical model revealed elevated [(64)Cu]CuCl(2) retention in the tumor mass. Following treatment with Dextran-Catechin, there was a significant reduction in radioactive uptake, as well as reduced tumor growth. Ex vivo analysis of tumors collected from Dextran-Catechin treated mice confirmed the reduced levels of CTR1. Interestingly, copper levels in blood were not affected by treatment, demonstrating potential tumor specificity of Dextran-Catechin activity. Conclusion: Dextran-Catechin mediates its activity by lowering CTR1 and intracellular copper levels in tumors. This finding further reveals a potential therapeutic strategy for targeting copper-dependent cancers and presents a novel PET imaging method to assess patient response to copper-targeting anticancer treatments. Ivyspring International Publisher 2018-11-09 /pmc/articles/PMC6276294/ /pubmed/30555570 http://dx.doi.org/10.7150/thno.29840 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Parmar, Arvind Pascali, Giancarlo Voli, Florida Lerra, Luigi Yee, Eugene Ahmed-Cox, Aria Kimpton, Kathleen Cirillo, Giuseppe Arthur, Andrew Zahra, David Rahardjo, Gita Liu, Guo Jun Lengkeek, Nigel Saletta, Federica Charil, Arnaud Kavallaris, Maria Vittorio, Orazio In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title | In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title_full | In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title_fullStr | In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title_full_unstemmed | In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title_short | In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis |
title_sort | in vivo [(64)cu]cucl(2) pet imaging reveals activity of dextran-catechin on tumor copper homeostasis |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276294/ https://www.ncbi.nlm.nih.gov/pubmed/30555570 http://dx.doi.org/10.7150/thno.29840 |
work_keys_str_mv | AT parmararvind invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT pascaligiancarlo invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT voliflorida invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT lerraluigi invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT yeeeugene invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT ahmedcoxaria invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT kimptonkathleen invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT cirillogiuseppe invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT arthurandrew invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT zahradavid invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT rahardjogita invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT liuguojun invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT lengkeeknigel invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT salettafederica invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT charilarnaud invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT kavallarismaria invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis AT vittorioorazio invivo64cucucl2petimagingrevealsactivityofdextrancatechinontumorcopperhomeostasis |